FTY720 (Fingolimod) Hydrochloride Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 590

Clinical Trials

Numerous clinical trials have evaluated the safety and efficacy of fingolimod across neurological conditions, primarily relapsing-remitting multiple sclerosis, stroke, and amyotrophic lateral sclerosis. Spanning Early Phase I to Phase IV, these studies are sponsored by major pharmaceutical companies such as Novartis and Biogen alongside academic centers like Massachusetts General Hospital. The overall portfolio reflects diverse recruitment statuses, including completed, active not recruiting, terminated, and withdrawn trials.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07483632	NOT_YET_RECRUITING	Relapsing Forms of Multiple Sclerosis	Biogen	2026-11-16	PHASE3
NCT06408259	RECRUITING	Multiple Sclerosis, Relapsing-Remitting	Bristol-Myers Squibb	2025-04-08	PHASE3
NCT07220252	RECRUITING	Relapsing Multiple Sclerosis	TG Therapeutics, Inc.	2026-07-01	PHASE2; PHASE3
NCT04480853	RECRUITING	Multiple Sclerosis	Novartis Pharmaceuticals	2020-10-12	PHASE4
NCT05285878	ENROLLING_BY_INVITATION	Interstitial Fibrosis; Kidney Transplant; Complications; Kidney Transplant Rejection; Kidney Transplant Failure and Rejection; Kidney Transplant Failure; Kidney Failure, Chronic; Graft Rejection	The Methodist Hospital Research Institute	2022-07-28	PHASE2
NCT06424067	RECRUITING	Non Small Cell Lung Cancer; Small-cell Lung Cancer	Medical University of South Carolina	2025-05-01	PHASE2
NCT03500328	ACTIVE_NOT_RECRUITING	Multiple Sclerosis, Relapsing-Remitting	Johns Hopkins University	2018-05-02
NCT04926818	ACTIVE_NOT_RECRUITING	Multiple Sclerosis (MS)	Novartis Pharmaceuticals	2021-10-05	PHASE3
NCT05307731	RECRUITING	Diabetes Mellitus, Type 2	General Hospital of Shenyang Military Region	2022-03-15	PHASE4
NCT04675762	UNKNOWN	Stroke; Inflammation	Second Affiliated Hospital, Zhejiang University, School of Medicine	2021-01-15	PHASE2
NCT06087965	UNKNOWN	Intracerebral Hemorrhage	Tang-Du Hospital	2023-10-11	PHASE1; PHASE2
NCT05123703	ACTIVE_NOT_RECRUITING	Relapsing-remitting Multiple Sclerosis	Hoffmann-La Roche	2022-05-19	PHASE3
NCT04667949	COMPLETED	Relapsing Multiple Sclerosis (RMS)	Novartis Pharmaceuticals	2021-02-20	PHASE4
NCT04353492	COMPLETED	Relapsing Multiple Sclerosis	Novartis Pharmaceuticals	2020-07-14	PHASE3
NCT02769689	UNKNOWN	Multiple Sclerosis	University Hospital, Clermont-Ferrand	2019-06-12	PHASE4
NCT04088630	COMPLETED	Intracerebral Hemorrhage; Cerebral Edema; Stroke Hemorrhagic; Intracerebral Hemorrhage, Hypertensive; Intracerebral Hemorrhage Intraparenchymal	Wake Forest University Health Sciences	2020-08-07	EARLY_PHASE1
NCT04629872	UNKNOWN	Stroke Inflammation	Ning Wang, MD., PhD.	2020-11-12	PHASE2
NCT04718064	UNKNOWN	Stroke	The Affiliated Hospital of Xuzhou Medical University	2021-02-01
NCT03943498	COMPLETED	Chemotherapy-Induced Peripheral Neuropathy; Numbness; Pain; Tingling	Mayo Clinic	2019-05-24	EARLY_PHASE1
NCT04657744	COMPLETED	Healthy	Genuine Research Center, Egypt	2020-08-10	PHASE1
NCT04280588	WITHDRAWN	Coronavirus Disease (COVID-19)	First Affiliated Hospital of Fujian Medical University	2020-02-22	PHASE2
NCT03941743	COMPLETED	Breast Carcinoma	Mayo Clinic	2019-12-12	PHASE1
NCT05141669	Completed	Multiple Sclerosis	Novartis Pharmaceuticals\|Novartis	2020-05-18	--
NCT02232061	COMPLETED	Multiple Sclerosis	Novartis Pharmaceuticals	2014-09-29	PHASE4
NCT03345940	TERMINATED	Relapsing Remitting Multiple Sclerosis	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	2017-04-30	PHASE4
NCT03257358	COMPLETED	Relapsing Multiple Sclerosis	Novartis Pharmaceuticals	2017-09-19	PHASE4
NCT01705236	COMPLETED	Relapsing Remitting Multiple Sclerosis RRMS	Novartis Pharmaceuticals	2012-08-20	PHASE4
NCT01201356	COMPLETED	Relapsing Forms of Multiple Sclerosis	Novartis Pharmaceuticals	2010-09-13	PHASE3
NCT02956200	WITHDRAWN	Stroke; Inflammation	Second Affiliated Hospital, Zhejiang University, School of Medicine	2016-11	PHASE2
NCT01633112	TERMINATED	Relapsing-remitting Multiple Sclerosis (RRMS)	Novartis Pharmaceuticals	2012-08-09	PHASE3
NCT02061137	COMPLETED	Rett's Syndrome	University Hospital, Basel, Switzerland	2013-08	PHASE1; PHASE2
NCT02490930	COMPLETED	Glioblastoma; Anaplastic Astrocytoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2015-07	EARLY_PHASE1
NCT01892722	ACTIVE_NOT_RECRUITING	Multiple Sclerosis	Novartis Pharmaceuticals	2013-07-26	PHASE3
NCT01941004	WITHDRAWN	Multiple Sclerosis (Relapsing Remitting)	Novartis Pharmaceuticals	2014-06	PHASE3
NCT03345940	Terminated	Relapsing Remitting Multiple Sclerosis	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta\|Patient-Centered Outcomes Research Institute\|Universita degli Studi di Genova	2017-04-30	Phase 4
NCT02575365	TERMINATED	Cognition; Brain Volume Loss	Novartis Pharmaceuticals	2016-02-16	PHASE4
NCT02373098	COMPLETED	Relapsing Remitting Multiple Sclerosis	Novartis Pharmaceuticals	2015-03-31	PHASE4
NCT01585298	COMPLETED	Multiple Sclerosis	Novartis Pharmaceuticals	2012-04-29	PHASE4
NCT02720107	COMPLETED	Relapsing-remitting Multiple Sclerosis	Novartis Pharmaceuticals	2016-05-12	PHASE4
NCT01625182	COMPLETED	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Novartis Pharmaceuticals	2012-12-22	PHASE3
NCT05684016	COMPLETED	Multiple Sclerosis, Relapsing-Remitting	George Washington University	2013-12
NCT02939079	COMPLETED	Multiple Sclerosis	Isfahan University of Medical Sciences	2015-04	PHASE2; PHASE3
NCT01779700	COMPLETED	Schizophrenia	Indiana University	2013-01	PHASE2
NCT02342704	TERMINATED	Relapsing-Remitting Multiple Sclerosis	Biogen	2014-11-30	PHASE4
NCT02325440	UNKNOWN	Relapsing Remitting Multiple Sclerosis	University Hospital Muenster	2014-03	PHASE4
NCT01647880	TERMINATED	Multiple Sclerosis	Charite University, Berlin, Germany	2013-07	PHASE2; PHASE3
NCT02575365	Terminated	Cognition\|Brain Volume Loss	Novartis Pharmaceuticals\|Novartis	2016-02-16	Phase 4
NCT03757338	COMPLETED	Healthy Volunteers	Asofarma S.A.I. y C.	2015-10-23	PHASE1
NCT05145621	COMPLETED	Bioequivalence; Safety	Alembic Pharmaceuticals Ltd.	2015-10-29	PHASE1
NCT01755871	TERMINATED	Relapsing Remitting Multiple Sclerosis	Heinrich-Heine University, Duesseldorf	2013-01	PHASE4
NCT01498887	COMPLETED	Relapsing Remitting Multiple Sclerosis	Novartis Pharmaceuticals	2011-12-24	PHASE4
NCT02307838	COMPLETED	Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis	Novartis Pharmaceuticals	2014-06	PHASE4
NCT01333501	COMPLETED	Multiple Sclerosis	Novartis Pharmaceuticals	2011-05	PHASE4
NCT01623596	COMPLETED	Relapsing Remitting Multiple Sclerosis	Novartis Pharmaceuticals	2012-06-08	PHASE4
NCT00731692	TERMINATED	Primary Progressive Multiple Sclerosis	Novartis Pharmaceuticals	2008-07-28	PHASE3
NCT02048072	COMPLETED	Multiple Sclerosis; Autonomic Nervous System Dysfunction	Jochen Vehoff	2013-07	PHASE4
NCT01578330	COMPLETED	Multiple Sclerosis; Relapsing-Remitting	Novartis Pharmaceuticals	2012-10	PHASE4
NCT02193217	COMPLETED	Relapsing-remitting Multiple Sclerosis	Tanabe Pharma Corporation		PHASE1
NCT02002390	COMPLETED	Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute	Tianjin Medical University General Hospital	2012-10	PHASE2
NCT01791192	WITHDRAWN	Acute Noninfectious Posterior, Intermediate, or Pan Uveitis	Novartis Pharmaceuticals	2013-11	PHASE2
NCT01786174	COMPLETED	Amyotrophic Lateral Sclerosis	Massachusetts General Hospital	2013-08	PHASE2
NCT01490840	TERMINATED	Fatigue in Multiple Sclerosis	Novartis Pharmaceuticals	2011-11	PHASE4
NCT01621269	WITHDRAWN	Multiple Sclerosis	Novartis Pharmaceuticals	2013-06	PHASE4
NCT01317004	COMPLETED	Relapsing Remitting Multiple Sclerosis	Novartis Pharmaceuticals	2011-05	PHASE4
NCT01757691	TERMINATED	Acute Demylelinating Optic Neuritis	Novartis Pharmaceuticals	2013-08	PHASE2
NCT01497262	COMPLETED	Multiple Sclerosis	Novartis Pharmaceuticals	2012-02	PHASE3
NCT01436643	TERMINATED	Depression; Relapsing-remitting Multiple Sclerosis	Novartis Pharmaceuticals	2011-11	PHASE4
NCT01709812	WITHDRAWN	Relapsing-remitting Multiple Sclerosis	Novartis Pharmaceuticals	2013-07	PHASE4
NCT01420055	COMPLETED	Multiple Sclerosis, Relapsing-Remitting	Novartis Pharmaceuticals	2011-08	PHASE4
NCT01534182	COMPLETED	Relapsing Remitting Multiple Sclerosis	Novartis Pharmaceuticals	2012-01	PHASE4
NCT01499667	TERMINATED	Relapsing Remitting Multiple Sclerosis (RRMS)	Novartis Pharmaceuticals	2011-09	PHASE3
NCT01216072	COMPLETED	Relapsing Forms of Multiple Sclerosis	Novartis Pharmaceuticals	2010-08	PHASE4
NCT01310166	COMPLETED	Relapsing-remitting Multiple Sclerosis	Novartis Pharmaceuticals	2011-02	PHASE4
NCT00670449	COMPLETED	Multiple Sclerosis	Novartis	2008-04	PHASE2
NCT01127750	COMPLETED	Relapsing Multiple Sclerosis	Novartis	2010-05	PHASE3
NCT00340834	COMPLETED	Multiple Sclerosis	Novartis	2006-05	PHASE3
NCT00355134	COMPLETED	Multiple Sclerosis	Novartis	2006-06	PHASE3
NCT00662649	COMPLETED	Multiple Sclerosis	Novartis	2008-02	PHASE3
NCT01199861	COMPLETED	Relapsing Multiple Sclerosis	Novartis	2010-08	PHASE3
NCT00333138	COMPLETED	Multiple Sclerosis	Novartis	2003-05	PHASE2
NCT00537082	COMPLETED	Multiple Sclerosis	Novartis	2007-09	PHASE2
NCT00289978	COMPLETED	Relapsing-remitting Multiple Sclerosis	Novartis	2006-01	PHASE3
NCT00785083	COMPLETED	Asthma	Novartis	2008-09	PHASE2
NCT00731523	COMPLETED	Renal Insufficiency	Novartis	2008-07	PHASE1
NCT00416845	COMPLETED	Healthy	Novartis	2006-10	PHASE1
NCT00239798	COMPLETED	Renal Transplantation	Novartis Pharmaceuticals	2004-11	PHASE2
NCT00239811	COMPLETED	Renal Transplantation	Novartis Pharmaceuticals	2004-04	PHASE3
NCT00239863	COMPLETED	Renal Transplantation	Novartis Pharmaceuticals	2004-05	PHASE3
NCT00099749	COMPLETED	Kidney Transplantation	Novartis Pharmaceuticals	2003-11	PHASE2; PHASE3
NCT00098735	COMPLETED	Kidney Transplantation	Novartis Pharmaceuticals	2004-04	PHASE3
NCT00099801	COMPLETED	Kidney Transplantation	Novartis Pharmaceuticals	2005-01	PHASE3
NCT00239876	COMPLETED	Renal Transplantation	Novartis Pharmaceuticals	2005-05	PHASE3
NCT00099736	COMPLETED	Kidney Transplantation	Novartis Pharmaceuticals	2003-05-07	PHASE3
NCT00239785	COMPLETED	Renal Transplantation	Novartis Pharmaceuticals	2003-04	PHASE3
NCT00239902	COMPLETED	Renal Transplantation	Novartis Pharmaceuticals	2002-05	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-19)

Check the FTY720 (Fingolimod) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Fingolimod functions as a sphingosine-1-phosphate receptor agonist that leads to receptor downregulation and blocks lymphocyte trafficking out of secondary lymphoid organs. By sequestering circulating lymphocytes within lymph nodes and inhibiting auto-immune neuroinflammation, this compound demonstrates clinical relevance in the management of multiple sclerosis and stroke.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).